Heparin-induced thrombocytopenia: 2008 Update

被引：3

作者：

Bartholomew J.R. ^{[1
]}

机构：

[1] Department of Vascular Medicine, Cleveland Clinic, Cleveland, OH 44195

来源：

Current Treatment Options in Cardiovascular Medicine | 2008年 / 10卷 / 2期

关键词：

International Normalize Ratio; Fondaparinux; Bivalirudin; Argatroban; Lepirudin;

D O I：

10.1007/s11936-008-0013-1

中图分类号：

学科分类号：

摘要：

Unfractionated heparin (UFH) and the low molecular weight heparin (LMWH) preparations are two of the most commonly prescribed medications in the hospital, and indications for their use are increasing. An increasingly recognized untoward effect of either UFH or LMWH is heparin-induced thrombocytopenia (HIT), a transient, prothrombotic condition that may result in venous or arterial thrombosis and amputation or death. This immune-mediated process generally develops within 4 to 14 days of administration, although it may occur more rapidly if there has been a recent exposure; it may even occur days to weeks after UFH or LMWH has been discontinued. Although once considered necessary for the diagnosis of HIT, thrombocytopenia is no longer essential. A 50% reduction in the platelet count from pre-heparin treatment levels is now considered a more specific finding. Prompt recognition, discontinuation of the offending agent, and initiation of an alternative anticoagulant are essential for prevention and/or treatment of these potentially devastating complications. Copyright © 2008 by Current Medicine Group LLC.

引用

页码：117 / 127

页数：10

共 51 条

[1]

Warkentin T.E., Heparin induced thrombocytopenia: Pathogenesis and management, Br J Haematol, 123, pp. 373-374, (2003)

[2]

Warkentin T.E., Levine M.N., Hirsh J., Et al., Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin, N Engl J Med, 332, pp. 1330-1335, (1995)

[3]

Prandoni P., Siragusa S., Girolami B., Fabris F., The incidence of heparin-induced thrombocytopenia in medical patients treated with low molecular weight heparin: A prospective cohort study, Blood, 106, pp. 3049-3054, (2005)

[4]

Oliveira G.B., Anstrom K.J., Honeycutt E.F., Et al., Days on intravenous heparin predict thrombocytopenia and drop in platelet count on heparin predicts mortality

[5]

findings from the Complications After Thrombocytopenia Caused by Heparin (CATCH) registry [abstract], Circulation, 110, SUPPL., (2004)

[6]

Mattel N., Lee J., Wells P.S., Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis, Blood, 106, pp. 2710-2715, (2005)

[7]

Cines D.B., Rauova L., Arepally G., Et al., Heparin-induced thrombocytopenia: An autoimmune disorder regulated through dynamic autoantigen assembly/disassembly, J Clin Apher, 22, pp. 31-36, (2007)

[8]

Warkentin T.E., Sheppard J.A.I., Testing from heparin-induced thrombocytopenia antibodies, Transfus Med Rev, 20, pp. 254-272, (2006)

[9]

Kelton J.G., The pathophysiology of heparin-induced thrombocytopenia: Biological basis for treatment, Chest, 127, (2005)

[10]

Bartholomew J.R., Begelman S.M., AlMahameed A., Heparin-induced thrombocytopenia: Principles for early recognition and management, Cleve Clin J Med, 72, SUPPL. 1, (2005)

← 1 2 3 4 5 6 →